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Abstract
A comprehensive approach to managing the vascular risk factors in both primary and secondary
stroke prevention settings can lower the risk of first and recurrent stroke. Recent studies highlight
the benefits of blood pressure treatment in the elderly, use of statins in healthy subjects with normal
low-density lipoprotein levels, and comparison of various anti-platelet agents. For acute stroke the
efficacy of thrombolysis beyond 3 hours has recently been shown.
Introduction and context
Stroke is the second most common cause of death
worldwide and the leading cause of disability, resulting
in a huge financial impact on our health care systems.
The lifetime direct and indirect cost of major types of
strokes was estimated to be in excess of $40 billion in the
USA in an incidence-based model assessed by Taylor and
colleagues for the year 1990 [1]. The incidence of stroke
steadily decreased from the early 1950s to the mid-
1980s. It then plateaued for a decade but is on the rise
again. There is a general consensus that the significant
decrease in stroke incidence was a result of better control
of risk factors. The recent increase in incidence is related
to the rising percentage of older people in the commu-
nity. This brief review will focus on three important areas
of recent advances in the management of cerebrovascular
diseases. Discussion relating to primary prevention
focuses on advances in management of hypertension
and hyperlipidemia. Secondly, we review recent devel-
opments in the use of appropriate antithrombotic
therapy in patients with transient ischemic attacks
(TIAs) and acute stroke. Finally, we review recent
advances in management of acute ischemic stroke to
limit neuronal damage, before reviewing the implica-
tions that all three areas have for clinical practice.
Recent advances
Primary prevention and cerebrovascular disease
Stroke is a heterogeneous disorder with varying under-
lying etiologies and associated modifiable vascular risk
factors. With early intervention, these modifiable risk
factors may be controlled and, hence, the incidence of
cerebrovascular events reduced.
Hypertension
Hypertension is the most common and important risk
factor for all types of strokes. Across World Health
Organization regions, research indicates that about 62%
of strokes and 49% of heart attacks are caused by high
blood pressure [2]. There is evidence that even high-
normal blood pressure (systolic 130-139 and diastolic
85-89 mmHg) is a marker of an elevated risk of
cardiovascular disease in both genders and the young
and the old (age range 35-90 years) [3,4]. About two-
thirds of the cerebrovascular disease burden is attribu-
table to non-optimum blood pressure control [2].
Multiple studies have shown a 30-40% reduction of
recurrent stroke with treatment of hypertension [5].
Benefits are seen irrespective of the class of antihyper-
tensive agents and the severity of hypertension [6].
Several categories of antihypertensive agents, including
thiazide diuretics, angiotensin-converting enzyme inhi-
bitors, angiotensin receptor blockers, adrenergic receptor
blockers, and calcium channel blockers, reduce cardio-
vascular risk, including the risk of stroke, in patients with
hypertension. The benefits of optimum blood pressure
therapy have been shown even in older people. A recent
prospective randomized placebo controlled study of
individuals ≥80 years of age with a sustained systolic
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outcome with antihypertensive treatment. In this study,
more than 3,800 individuals were enrolled, of whom
only 11.8% had cardiovascular history, and were treated
with indapamide (1.5 mg) with or without perindopril
(2-4 mg). A mean blood pressure reduction of
15/1 mmHg was achieved in the active arm compared
to placebo. A significant 39% reduction in the stroke-
related death rate was noted at 2 years (P = 0.05). A 30%
reduction in fatal and non-fatal strokes (P = 0.06) and a
64% reduction in heart failure (P=0.001) was achieved
[7]. These findings give credence to both the efficacy and
the safety of treating hypertension in very old people.
In summary, there is compelling evidence that treatment
of hypertension is associated with a significant reduction
of first ever stroke and stroke-related death in the young
and the old. The cornerstone to successful outcome is
instituting sustained lifestyle changes and early pharma-
cotherapy to achieve target goals as recommended by the
Canadian Hypertension Education Program (CHEP)
2009 (<140/90 mmHg; <130/80 mmHg in diabetes
and renal failure) [8]. The choice of antihypertensive
therapy may be dictated by other cardiovascular
conditions.
Dyslipidemia
There is no clear evidence of an association between
rising levels of serum cholesterol and the risk of
cerebrovascular disease. There is, however, evidence
from randomized trials that statins can reduce the risk
of stroke. In the Heart Protection Study the incidence of
first ever stroke was reduced by 29% with simvastatin
compared to placebo [9]. This effect was seen indepen-
dent of a history of previous vascular disease and the
level of serum cholesterol levels. Other studies have
shown similar results [10].
The recently published JUPITER trial (which included
17,802 patients) tested the effects of rosuvastatin versus
placebo in otherwise healthy subjects with normal low-
density lipoprotein (LDL) levels (<3.4 mmol/L) and
elevated high-sensitivity C-reactive protein (≥2 mg) and
showed significant reductions in major cardiovascular
events (16% in stroke, P = 0.002; 20% in myocardial
infarction, P = 0.002; and 40% in the composite end-
point of myocardial infarction, stroke, revascularization
and death, P = 0.00001). The median LDL and high-
density lipoprotein levels were 2.8 and 1.3 mmol/L,
respectively, in both active and placebo arms. Rosuvas-
tatin reduced LDL by 50% and C-reactive protein by
37%. There was no difference in intracranial hemorrhage
between the two groups (six in the rosuvastatin group
and nine in the placebo group) [11].
A single large trial, the Stroke Prevention by Aggressive
Reduction in Cholesterol Levels (SPARCL) trial, studied
the use of statins in patients with cerebrovascular disease
without cardiac history. This trial randomized 4,731
patients with LDL levels of 2.6-4.9 mmol/L to receive
atorvastatin 80 mg or placebo. The 5-year absolute risk
reduction for fatal and non-fatal stroke was 2.2%
(unadjusted hazard ratio P =0 . 0 5 ) a n d f o r m a j o r
cardiovascular events was 3.5% (P = 0.002). This overall
reduction in the incidence of stroke and other cardio-
vascular events was noted despite a small increase in
hemorrhagic strokes [12].
Secondary prevention and cerebrovascular disease
The risk of a completed stroke in patients with a TIA is
approximately 10.5% at 90 days. This is especially high
in patients with a history of hypertension or diabetes,
in whom the neurological symptoms last for over
10 minutes and consist of focal weakness or aphasia.
The 2-dayrisk of stroke in such patients maybe as high as
8% [13]. Recent evidence from two independent studies
has shown that the 90-day risk can be reduced by as
much as 80% if patients are evaluated and their
treatment initiated within 24 hours of the onset of
symptoms [14,15]. It is imperative that we improve our
ability to rapidly asses and manage such patients. In
addition to the liberal use of antihypertensive and statin
therapy, as outlined above in the discussion on primary
prevention, such patients also require immediate antith-
rombotic therapy.
Antithrombotic treatment options are limited to aspirin
[acetylsalicylic acid (ASA)], clopidogrel, and a combi-
nation of ASA and extended release dipyridamole
(ASA+ERDP). The recently published guidelines on
antithrombotic therapy would suggest that any one of
the three agents is indicated as the first-line therapy for
stroke prevention in patients with TIA or ischemic stroke
of non-cardiac origin. [16] Clopidogrel and ASA+ERDP
are, however, significantly more expensive than ASA and
may have relatively more side effects. Studies have
compared the relative efficacy of ASA to clopidogrel or
ASA to ASA+ERDP. In such studies, these agents have
shown better results when compared to ASA. The effect
has been marginal with clopidogrel (absolute difference
0.5% and relative risk reduction 11%) [17]. With
ASA+ERDP, this effect was more robust (relative risk
reduction of 37%) [18].
Until recently, however, no studies had compared
clopidogrel to ASA+ERDP in stroke prevention. The
Prevention Regimen for Effectively Avoiding Second
Strokes (PRoFESS) trial published last year was the
first large study to compare the efficacy of clopidogrel to
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20,000 patients were followed for 4 years and the
primary outcome was the occurrence of recurrent
ischemic stroke. Secondary outcomes included the
incidence of serious complications, including develop-
ment of systemic or intracerebral hemorrhage. There was
no significant difference in the development of recurrent
stroke in the two treatment groups. There were, however,
more complications, including an increased risk of
intracerebral hemorrhage, in the ASA+ERDP-treated
group. Despite the excess in hemorrhagic strokes, the
number of patients with fatal or disabling strokes was
s i m i l a ri nb o t hg r o u p s[ 1 9 ] .I na n t i p l a t e l e tn a ï v e
patients, it is our preference to start patients on ASA as
the first-line therapy. Patients who are unable to tolerate
ASA may be treated with clopidogrel.
At present there is no evidence that the combination of
ASA with clopidogrel is superior to the use of single-
agent treatment. Such combinations are routinely used
in patients with acute coronary syndromes or in patients
who require arterial stenting. The Management of
Atherothrombosis with Clopidogrel in High-risk Patients
with Recent TIA or Ischemic Stroke (MATCH) study
showed that the combination was no better than
clopidogrel alone, but did increase the risk of sympto-
matic intracerebral hemorrhage in patients with stable
TIAs or ischemic stroke [20]. The combination is there-
fore not recommended in stroke prophylaxis. A recent
preliminary study, the Fast Assessment of Stroke and
Transient Ischaemic Attack to Prevent Early Recurrence
(FASTER) trial, however, showed that in the very acute
phase after onset of a TIA, the combination might be
superior to ASA alone [21]. FASTER was, however, a
feasibility study. A larger FASTER II study is in the
planning stages and may answer this important question
on the use of combination antithrombotic therapy for a
short time in patients very early after presenting with
a TIA.
Management of acute stroke
Thrombolysis
Thrombolysis using intravenous tissue plasminogen
activator (tPA) has been available as a treatment for
acute ischemic stroke for more than a decade. Until
recently, the use was limited to only a 3-hour treatment
window from the time of onset of the symptoms. This
narrow therapeutic window resulted in a low rate of
thrombolysis. Recently, the European Cooperative Acute
Stroke Study (ECASS) III study assessed efficacy of
intravenous tPA up to 4.5 hours from the time of onset
of stroke symptoms [22]. The study was carried out
in multiple centers in Europe. This study enrolled
821 patients between 3 and 4.5 hours after stroke onset.
The primary end point was disability at 90 days,
dichotomized as a favorable outcome (a score of 0 or 1)
or an unfavorable outcome (a score of 2 to 6) on the
modified Rankin Scale (mRS). The secondary end point
was a global outcome analysis of four neurological and
disability scores combined. Safety end points included
death, symptomatic intracranial hemorrhage, and other
serious adverse events. The outcome was in favor of tPA
(52.4 versus 45.2%, P = 0.04). The incidence of intracra-
nial hemorrhage was higher with tPA than with placebo
(for any intracranial hemorrhage, 27.0 versus 17.6%,
P = 0.001; for symptomatic intracranial hemorrhage, 2.4
versus 0.2%, P = 0.008). Mortality did not differ
significantly between the tPA and placebo groups (7.7
and 8.4%, respectively; P = 0.68) [22]. It is expected that,
with the results of ECASS III, health regulatory bodies in
North America, Europe and elsewhere would soon be
recommending an extension of the treatment window
withtPAto4.5hoursineligiblepatientswithacutestroke.
Despite the positive outcome in the extended therapeutic
window, very early treatment remains the goal for good
outcome and, therefore, ultra-fast intervention must be
ensured.
Stroke units
Stroke care can be optimized by enhancing transition
from the emergency room to a specialized stroke unit
with stroke expertise in nursing care, cardiac monitoring,
early physiotherapy with rapid initiation of aggressive
post-stroke rehabilitation and multidisciplinary dispen-
sation planning. Randomized studies have confirmed
association of improved outcomes with designated
stroke units in terms of reduced mortality, functional
independence and need for institutionalized care after
the stroke [23]. This beneficial effect has been shown to
be consistent [24] and also seen in a routine clinical
practice in a large multicenter observational study
analyzing more than 17,000 ischemic stroke admissions
across a large Australian population [25]. Hospitals are
encouraged to develop such units if they admit stroke
patients regularly. Admission to stroke units would
significantly decrease the risk of complications, reduce
the length of stay, and allow for a larger percent of
patients to be discharged home.
Decompressive hemicraniectomy for large strokes
Recently, in three randomized studies, hemicraniectomy
performed within 48 hours of stroke onset has been
compared to medical management alone. A pooled
analysis of patients (93 patients aged <60 years) with
malignant stroke in the middle cerebral artery territory
indicated a significantly lower 1-year mortality with a
probability of survival increasing from 28 to 80% and a
significantly larger proportion with a 1-year outcome of
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to medical management alone (n = 42) [26]. The
functional outcome does not appear to improve if
hemicraniectomy is delayed beyond 48 hours [27].
However, the relevance of hemispheric dominance, the
extension of infarcted brain, and whether the reduced
mortality justifies the morbidity among survivors remain
to be answered. The decision to perform hemicraniect-
omy in patients with massive brain infarction must be
made on an individual basis and in centers with such
experience.
Implications for clinical practice
Hypertension and hyperlipidemia
Multiple studies show significant reduction in the
incidence of stroke with hypertension treatment. Even
in the very old, treatment of hypertension does not
impact negatively. Therefore, judicial use of antihyper-
tensives should be considered for optimum blood
pressure control.
There is evidence from several trials in high-risk patients
without cerebrovascular disease that treatment with
statins will significantly reduce the risk of stroke. SPARCL
showed that this effect was also evident in patients with
established cerebrovascular disease. Canadian, USA, and
European guidelines recommend that in high-risk
patients with cerebrovascular disease, LDL levels should
be targeted to less than 2 mmol/L. This requires the use
of high dose statins in most patients.
Secondary prevention and cerebrovascular disease
Early intervention should be instituted in patients with
high-risk TIAs. There is no strong evidence for dual
antiplatelet therapy in stroke prevention. We consider
aspirin as the first antiplatelet choice in aspirin-naïve
patients unless there is intolerance to aspirin. There is
some evidence that short-term combination of ASA and
clopidogrel may be more efficacious in the acute phase,
however, the latter warrants further evidence. Optimum
antithrombotic prophylaxis, blood pressure and choles-
terolmanagementtocurrentlyrecommendedtargetsmust
be implemented to reduce recurrence of TIA or stroke.
Management of acute stroke
The window for thrombolytic treatment of acute
ischemic stroke is expected to be extended to 4.5 hours
but ultra-rapid revascularization remains the goal to
realize best neurological and functional outcomes.
Specialized post-stroke care in stroke units helps mitigate
medical complications, and early rehabilitation leads to
better recovery and independence. Following a malig-
nant anterior circulation stroke the decision about
craniectomy must be individualized.
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